# ComPareNET (NCT05247905)

> Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05247905
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Unresectable Pancreatic Neuroendocrine Carcinoma
- Interventions: Lutetium Lu 177 Dotatate; Capecitabine; Temozolomide; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 31
- Primary outcome: Progression free survival (PFS)

## Indexed commentary on ComPareNET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=comparenet-nct05247905